Despite advances in understanding the complexities of acute myeloid leukaemia (AML), the
treatment of refractory or relapsed AML (rrAML) remains a daunting clinical challenge.The
investigators designed a new regimen, including chidamide, decitabine, aclarubincin,
cytarabine and G-CSF, to treat rrAML.